Aim: To evaluate the safety of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), and its effects on body weight management in adults without diabetes.
| INTRODUCTION
Obesity is a major risk factor for a variety of metabolic diseases, including cardiovascular disease (CVD), diabetes, musculoskeletal disorders and some cancers. [1] [2] [3] [4] Weight loss can lead to a reduction in obesity-related complications, including the risk of developing diabetes. [5] [6] [7] In overweight (body mass index [BMI] ≥25 kg/m 2 and-<30 kg/m 2 ) or obese people (BMI ≥30 kg/m 2 ) who have progressed to type 2 diabetes (T2D), weight loss is associated with reductions in glycated haemoglobin (HbA1c), improvements in CVD risk factors and reductions in mortality. [8] [9] [10] Weight reduction through lifestyle interventions alone can be challenging. 11 Options for effective pharmacological treatments are limited, and those available require daily dosing. There is an unmet need for effective weight loss treatment with less frequent dosing, which could help facilitate better adherence and sustainability of weight loss. 12 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are wellestablished therapeutic options for T2D. 13, 14 Another benefit of GLP-1RA treatment is weight loss, which has been demonstrated in overweight or obese people with or without T2D. 15 GLP-1RAs reduce body weight by promoting satiety and reducing food intake, through peripheral and potentially through direct actions on the central nervous system (CNS). [16] [17] [18] The anorectic effects of GLP-1RAs appear to be independent of their effects on gastrointestinal (GI) motility and tolerability. 19 Efpeglenatide (formerly HM11260C) is currently being developed to improve glycaemic control in people with T2D as a once-weekly subcutaneous (s.c.) administration. Efpeglenatide is a long-acting GLP-1RA that is a single amino acid-modified exendin conjugated to a fragment crystallizable region of human immunoglobulin 4 via a 3.4-kDa mini-polyethylene glycol linker. 20, 21 The fragment crystallizable conjugation in efpeglenatide allows a long duration of action and a pharmacokinetic/pharmacodynamic profile that could support a flexible dosing frequency (once weekly, once every 2 wk and once monthly). Indeed, in a single ascending-dose study in people with T2D, efpeglenatide demonstrated a half-life of 5.6 to 7.5 d. 22 In a previous phase II study (NCT01452451), once-weekly or once-monthly administration of efpeglenatide resulted in significant weight loss and glycaemic improvements compared with placebo in people with T2D on stable metformin monotherapy after 8 and 11 wk (three monthly doses) of treatment, respectively. 23 Efpeglenatide once weekly (over 12 wk) and once monthly (over 16 wk) has been demonstrated to significantly improve glycaemic control and decrease body weight versus placebo in people with T2D in the phase II EXCEED 203 (NCT02057172) 24 and LIBERATE 204 (NCT02081118) trials, 25 respectively.
The objective of the present BALANCE phase II trial (NCT02075281) was to assess the safety and tolerability of s.c. efpeglenatide once weekly or once every 2 wk, in combination with a hypocaloric diet, and its potential to reduce body weight in obese or overweight people (with comorbidity), and without diabetes, over 20 wk of treatment.
| METHODS

| Trial design and participants
BALANCE was a multinational, double-blind, randomized, placebocontrolled, parallel-group study that was initiated in April 2014 and completed in February 2015. The study comprised a screening period, a 2-wk dose titration period (only the once-every-2-wk doses were titrated) and an 18-wk constant-dose treatment period, with a 6-wk follow-up period ( Figure S1 ). The study was designed and conducted in accordance with the International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by the institutional review boards or ethics committee at each study site, and each participant provided written informed consent.
Eligible participants were aged ≥18 y and <65 y at screening and in stable health, with a fasting plasma glucose (FPG) of <7 mmol/L (<126 mg/dL) and a BMI of ≥30 kg/m 2 . People with BMI ≥27 kg/m 2 and <30 kg/m 2 were also eligible if they had treated or untreated comorbidities, such as hypertriglyceridaemia, dyslipidaemia, hypertension, glucose intolerance (based on medical history) or sleep apnoea; these participants represent a population with obesity-related risk factors, thereby allowing the evaluation of the potential for efpeglenatide to reduce the incidence of these conditions (in addition to reducing body weight). Participants were excluded from the study if they had a BMI of >42 kg/m 2 , drug-induced obesity (also referred to as iatrogenic obesity), known diabetes or an HbA1c >48 mmol/mol (>6.5%; see Supporting Information for full details).
| Interventions
On day 1, all eligible participants were randomized 1:1:1:1:1 via an interactive voice/web response system to efpeglenatide 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk, or placebo. Participants, investigator staff, persons performing the assessments and data analysts were blinded to the treatment from the time of randomization until database lock. Participants received training on the injection method and self-administered the study drug in the morning s.c. in the abdomen using a pre-filled syringe. The first injection was on day 1 for participants in all treatment arms, with no period of adaptation to the injection device. All participants receiving efpeglenatide once every 2 wk started on 4 mg (day 1) and were titrated to their assigned dose in week 2 of the 2-wk titration period; participants in the once-weekly arms received their assigned dose without any titration during this period ( Figure S1B ). Participants were assessed at regular intervals over the treatment period, with three follow-up evaluations post-treatment ( Figure S1B ). Throughout the study, participants were instructed by study staff to adhere to a hypocaloric diet (~500 kcal/day deficit) and encouraged to increase physical activity; however, caloric intake and physical activity were not controlled.
| Study endpoints
The primary efficacy endpoint was change from baseline (day 1 or last value observed prior to randomization if this was not available) in body weight to week 21 (ie, after 20 wk of treatment). Additional endpoints derived from body weight were per cent change in body weight from baseline, change in BMI from baseline and percentage of participants with ≥5% or ≥10% of body weight reduction from baseline to week 21. Change from baseline in waist circumference was also measured. A description of body weight and waist circumference measurements is provided in the Supporting Information. Glucose metabolism variables were measured at the central laboratory and included changes from baseline to week 21 in FPG and HbA1c levels.
Lipid assessments included change from baseline to week 21 in total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol and triglycerides.
Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, 12-lead ECG variables, clinical laboratory assessments, injection-site reactions and immunogenicity. Blood samples were collected to assess the development of anti-efpeglenatide antibodies, which were determined by enzyme-linked immunosorbent assay. Neutralizing antibodies were determined using a cell-based assay. The incidence of symptomatic hypoglycaemia was reported by participants in study diaries (with an alert value of FPG ≤3.9 mmol/L [≤70 mg/dL]), rather than by a specific laboratory measurement.
Severe symptomatic hypoglycaemia was indicated by a participant requiring assistance from another person to actively administer carbohydrates or glucagon, or take other corrective actions. Participants were instructed to record adverse events (AEs), in particular, symptomatic hypoglycaemia, nausea and vomiting, and injection-site reactions in a daily diary provided to them. For percentage of participants who lost ≥5% or ≥10% of body weight from baseline to week 21, Fisher's exact test was used to test whether the null hypothesis of equal proportions held or did not hold between treatment group and placebo. All other efficacy endpoints were summarized descriptively by treatment group and visit, and analysis was performed using the same method as for the primary efficacy analysis.
| Statistical analysis
All efficacy endpoints were analysed using the full analysis set, which consisted of all participants who received the study drug and had at least one assessment recorded after dosing; participants were grouped according to their randomized treatment. For the primary efficacy analysis, supporting analysis was also performed on the perprotocol population (all participants in the full analysis set who did not experience any major protocol violations that could have potentially impacted the primary efficacy endpoint). All safety endpoints were analysed using the safety set, which consisted of all participants who received any study drug, and study participants were grouped according to the treatment they actually received. An interim analysis was performed for administrative purposes, to aid in the planning of future studies in this developmental programme. The CI for the final endpoint was adjusted to 95.1% (α level of 0.049) to account for α spending for the interim analysis (α level 0.0031) based on the O'Brien-Fleming function. A list of important changes to methodology after trial initiation is provided in the Supporting Information.
| RESULTS
| Participant disposition and baseline characteristics
Overall, 297 participants were enrolled and randomized in the study, with 237 participants assigned to one of four efpeglenatide groups and 60 participants assigned to placebo ( Figure S2 ). Study participation by country and by site is shown in Table S1 . A total of 295 participants received the study drug (efpeglenatide overall, n = 235; placebo, n = 60) and were included in the safety set (note: two participants withdrew from the study prior to receiving the study drug and were not included in the safety set). Of the enrolled population, a total of 216 participants completed the 20-wk treatment period (efpeglenatide overall, n = 168; placebo, n = 48) and 207 completed the follow-up period (efpeglenatide overall, n = 160; placebo, n = 47
[ Figure S2 ]). Discontinuation rates (for the safety set) over the 20-wk treatment period were 25% to 31% with efpeglenatide and 20% with placebo. For the overall study period (20-wk treatment and 6-wk follow-up), discontinuation rates (for the safety set) were 29% to 34% with efpeglenatide and 22% with placebo. Across all the efpeglenatide groups, AEs were the most common reasons for study discontinuation (efpeglenatide, 5%-19%; placebo, 5% [safety set]).
Demographic and baseline characteristics were similar across the treatment groups (Table 1) . Overall, the majority of participants (95%) were obese (BMI ≥30 kg/m 2 ) and 5% of participants were overweight (BMI 27 to <30 kg/m 2 [safety set]).
| Body weight and related variables
All doses of efpeglenatide led to significant reductions in body weight from baseline to week 21 (ie, after 20 wk of treatment) compared with placebo ( Figure 1A ,B and Table 2 ). Differences in LSM change from baseline to week 21 versus placebo with efpeglenatide 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk and 8 mg once every 2 wk were −6.5 kg, −7.2 kg, −6.3 kg and −6.9 kg, respectively (P < 0.0001 for all comparisons; Figure 1B and Table 2) ; this difference was greatest in the 6-mg-once-weekly group. Similar results were observed on analysis using the per-protocol population, and on sensitivity analysis using last observation carried forward and pattern mixture model (Table S2) .
Change from baseline in body weight to week 21 was also significant, with all efpeglenatide doses compared with placebo, when measured as per cent changes from baseline (differences in LSM changes from baseline vs. placebo were −6.8%, −7.4%, −6.7% and −7.5% with 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk and 8 mg once every 2 wk, respectively; P < 0.0001 for all).
At each visit through week 21, LSM decreases from baseline in body weight in each efpeglenatide group were greater compared with placebo, and were further decreased at each successive time point, whereas in the placebo group, the LSM change from baseline varied little ( Figure 1A ).
Significantly higher proportions of participants lost ≥5% or ≥10% of baseline body weight at week 21 across the efpeglenatide groups (45.8%-53.4% and 18.6%-27.1%, respectively) compared with placebo (3.3% and 1.7%, respectively, P < 0.0001 and P < 0.01 for all comparisons vs. placebo, respectively [ Figure 1C ]). Efpeglenatide 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk and 8 mg once every 2 wk also led to significantly greater reductions in waist circumference from baseline versus placebo, with LSM differences from baseline versus placebo of −4.4 cm, −5.9 cm, −5.3 cm and −7.5 cm, respectively (P < 0.01 for all; Table 2 ). Reductions in BMI were also significant in all efpeglenatide groups compared with placebo ( 
| Glycaemic endpoints
At each visit through week 21, all efpeglenatide groups were associated with decreases from baseline in FPG, while increases from baseline were observed with placebo ( Figure S3A ; P < 0.01 for all comparisons of LSM changes vs. placebo at week 21 [ Table S3 ]).
Decreases in HbA1c were also observed in all efpeglenatide groups at every visit throughout the treatment period, but not with placebo ( Figure S3B ; P < 0.0001 for all comparisons of LSM changes vs. placebo at week 21 [ Table S3 ]). (Table S4 and Figure S4A ; P < 0.01 for all comparisons vs. placebo). All doses of efpeglenatide also led to significant reductions in LDL cholesterol and VLDL cholesterol levels versus placebo (P < 0.05 for all comparisons; Table S4 and Figure S4B ,C).
Efpeglenatide 6 mg once weekly, 6 mg once every 2 wk and 8 mg once every 2 wk led to significant reductions in HDL cholesterol at week 21 versus placebo (P < 0.05 for all); however, the difference in LSM change from baseline versus placebo with 4 mg once every 2 wk was not statistically significant (−0.06 mmol/L; P = 0.0520 [Table S4 and Figure S4D] ). All doses of efpeglenatide led to significant reductions in triglycerides compared with placebo at week 21 (Table S4 and Figure S4E ). Week 21 experienced four or more episodes (Table S5 ). In the efpeglenatide groups overall, there were 15 severe GI AEs that were reported in a total of eight participants (Table 3 ). In participants receiving efpeglenatide, most TEAEs leading to discontinuation were GI disorders; none of these GI AEs were classified as serious AEs (Table S6) 
|
| Heart rate and blood pressure
Significant increases from baseline to week 21 in heart rate were observed in all the efpeglenatide groups (range of LSM change from baseline vs. placebo: 3.1-5.7 bpm), which were within the expected range for GLP-1RAs (Table S7) Table S7 ).
| Other safety assessments
During the treatment period, one participant in the placebo group had a high level of amylase (>300 U/L) with no sign of pancreatitis. High lipase values (>153 U/L) were recorded in 11 participants in the efpeglenatide group (4 mg once weekly: four participants; 6 mg once weekly: two participants; 6 mg once every 2 wk: three participants; 8 mg once every 2 wk: two participants).
At baseline, 2.6% of participants (6/235) in the efpeglenatide group overall were positive for anti-efpeglenatide antibodies (Table S7) Injection-site reactions occurred for both efpeglenatide (8.5%-18.6%) and placebo (21.7%; Table 3 ).
| DISCUSSION
In this trial, efpeglenatide administered once weekly (4 mg, 6 mg) and lost ≥10% of baseline body weight; these proportions were statistically significant versus the placebo group, in which <5% of participants met these targets. However, the long-term effects of efpeglenatide on body weight reduction (eg, >1 y) have not yet been assessed.
Treatment benefits appeared to be related to dose. The mean reductions in body weight and BMI endpoints from baseline (vs. placebo) were greater with the higher doses of efpeglenatide once weekly and once every 2 wk compared with the respective lower doses of the same dosing regimen ( Table 2 ). The higher doses of the efpeglenatide once-weekly and once-every-2-wk regimens were associated with similar reductions (vs. placebo) in body weight and BMI.
Reductions in body weight and BMI endpoints (vs. placebo) were also comparable between the lower doses of efpeglenatide once weekly and once every 2 wk.
Treatment with efpeglenatide also led to significant improvements in other metabolic variables, including glucose metabolism and lipid profiles. Although the participants in this trial did not have diabetes, all doses of efpeglenatide significantly reduced FPG and HbA1c levels compared with placebo. Significant reductions in blood lipids, including total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol and triglycerides were also observed with most doses of efpeglenatide versus placebo. Blood pressure tended to decrease with efpeglenatide, although the reduction was only significant with the 6-mg once-weekly dose. As the baseline blood pressure of the participants in this study was in the normal range, the potential for efpeglenatide to improve blood pressure in people with high blood pressure remains to be examined.
Efpeglenatide was generally well tolerated, and most TEAEs were mild or moderate in intensity. The most frequently reported TEAEs were GI disorders, consistent with the GLP-1RA class. 27 Most nausea and vomiting events occurred over the first few injections and subsided over time. As slow titration of GLP-1RAs has been shown to mitigate GI side effects, [27] [28] [29] [30] the tolerability of efpeglenatide should be assessed with a more optimal titration scheme than that used in the present study. It is worth noting that, while rates of GI disorders were high with efpeglenatide, they were comparable to those observed in phase II studies of semaglutide and liraglutide in people with obesity. 31, 32 Increases in heart rate and decreases in blood pressure observed in the present study were within the expected range for GLP-1RAs. 27 While exendin-based GLP-1RAs are generally associated with high immunogenicity, 33, 34 the immunogenicity of efpeglenatide was relatively low, with~20% of efpeglenatide-treated participants developing anti-drug antibodies. While overall discontinuation rates with efpeglenatide appeared to be slightly higher in this phase II study compared with studies of other GLP-1RAs in obesity, discontinuations attributable to AEs were similar. 31, 32 Among the currently available GLP-1RAs there is variability in their effects on weight loss in people with T2D. 35 Although the exact mechanism underlying these differences is unclear, it is possible that they involve access to GLP-1 receptors that mediate weight loss, some of which may be in the CNS. 36, 37 It is unknown whether efpeglenatide crosses the blood-brain barrier; however, it is possible that the fragment crystallizable conjugation may prevent effective transport into the CNS. Nevertheless, the magnitude of weight loss in participants with obesity observed with efpeglenatide in the present study was comparable to that observed with liraglutide, a smaller GLP-1RA that is approved for obesity as a once-daily injection. 38 In a 20-wk, phase II clinical trial, liraglutide 3.0 mg once daily led to a placebo-subtracted reduction in body weight of 4.4 kg (95% CI 2.9-6.0) in people with obesity and without diabetes. 31 In BALANCE, the placebo-adjusted per cent change in weight from baseline with efpeglenatide ranged between −6.7% and −7.5% after 20 wk of treatment (placebo-adjusted mean weight loss: 6.3-7.2 kg). In people with obesity without diabetes, s.c. semaglutide once daily demonstrated a treatment difference in weight change from baseline versus placebo of between −4.6% and −15.7% at 52 wk. 32 Although the observed reduction in weight by efpeglenatide once weekly and semaglutide once daily cannot be directly compared, especially owing to the difference in endpoint timings and treatment regimens, the 52-wk reduction by semaglutide suggests the potential for treatment with GLP-1RAs to demonstrate clinically significant weight reduction at 52 wk.
The potential for clinically meaningful weight loss is particularly apparent if higher total weekly doses of GLP-1RAs are used for weight reduction compared with the doses used to achieve glycaemic control, as demonstrated by semaglutide, 32, 39 although this is yet to be determined for efpeglenatide. It is important to note that weight reduction with efpeglenatide did not appear to plateau at 20 wk, suggesting the potential for further weight loss at later time points.
Biochemical and preclinical studies suggest that efpeglenatide has unique receptor properties that may explain the greater maximal GLP-1 receptor signalling and reduced desensitization seen with efpeglenatide versus other GLP-1RAs following chronic exposure in vitro. 21, 40 Efpeglenatide is associated with faster dissociation kinetics from the GLP-1 receptor compared with other GLP-1RAs, allowing efpeglenatide to function as a full agonist for glucose-stimulated insulin secretion but with reduced agonist-induced receptor internalization, resulting in more cell-surface receptor availability with chronic exposure in vitro. 21 Whether these unique receptor properties will translate to better weight loss effects of efpeglenatide compared with other GLP-1RAs in patients remains to be investigated.
There were several limitations to this study. As this was a phase II study, the small sample size may have limited the statistical power needed to detect significance for some endpoints, and we did not control for multiplicity of P values. Although multiple analyses were used to handle missing data, it is important to note that the magnitude of weight loss described using these analyses in clinical trials may not reflect what occurs in the real-world setting. The effect of study drug discontinuation on weight loss was not analysed in this study. Additionally, the relatively short duration of the study did not allow assessment of maximal weight loss or sustainability of weight loss, and the dose range tested was not sufficient to explore the full dose-response relationship. While participants were encouraged to reduce caloric intake and exercise, diet and physical activity were not actively controlled. Weight loss in the placebo group was minimal, suggesting that the guidance on diet and exercise may not have been effective in promoting weight loss. Finally, this study did not include a titration period for the once-weekly doses, and it used a short titration period for the once-every-2-wk doses. The safety profile, particularly the incidence of GI AEs, should be further investigated using optimized titration.
In conclusion, efpeglenatide once weekly and once every 2 wk was well tolerated, and treatment was associated with a significant and clinically meaningful reduction in body weight in obese or overweight people (with comorbidity) without diabetes. The weight loss effects were associated with improvements in glycaemic and lipid variables, consistent with an overall benefit with regard to metabolism.
These findings support further development of efpeglenatide in obese people. Future studies are needed to assess the effects of higher doses as well as the long-term safety and efficacy, and improvements in health outcomes including comorbidities associated with obesity.
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